Trial Search: "Kidney"



Treatment trials which apply specifically to your search:


0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-19-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

Treatment:
(No treatments specified)

0C-19-16

Trial Leaders:
Heinz Josef Lenz

PhI-112: A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-20-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Treatment:
Immunotherapy

0C-20-10

Trial Leaders:
Anthony El-Khoueiry

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

Treatment:
Other

0C-20-13

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies

Treatment:
Other

0C-20-14

Trial Leaders:
Jorge Nieva

Tumor-agnostic precision immunooncology and somatic targeting rational for you (TAPISTRY) Phase II Platform trial

Treatment:
Immunotherapy

0C-20-18

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)

Treatment:
Other

0C-20-19

Trial Leaders:
Jacob Thomas

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab In Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

Treatment:
Other

0C-21-13

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers

Treatment:
Immunotherapy

0C-21-14

Trial Leaders:
Jacob Thomas

A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-21-17

Trial Leaders:
Heinz Josef Lenz

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Treatment:
Other

0C-21-18

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of ASP1570 in Participants with Advanced Solid Tumors

Treatment:
Immunomodulator

0C-22-11

Trial Leaders:
Jacob Thomas

A Phase 1/2 Study of BA3071 in Combination with Nivolumab in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-22-20

Trial Leaders:
Diana Hanna

A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications

Treatment:
Immunotherapy

0C-22-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Cemiplimab in Patients with Advanced Cancers

Treatment:
Immunotherapy

0C-22-4

Trial Leaders:
Diana Hanna

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-22-6

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients with Select Advanced or Metastatic Solid Tumors

Treatment:
Immunotherapy

0C-22-7

Trial Leaders:
Jacob Thomas

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes.

Treatment:
Immunomodulator

0C-23-4

Trial Leaders:
Anthony El-Khoueiry

Phase I/II First-in-Human Study of TT-10 as a Single Agent in Participants with Advanced Selected Solid Tumors

Treatment:
Immunotherapy

0C-23-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2 dose-escalation and expansion study of ST316 in subjects with selected advanced unresectable and metastatic solid tumors

Treatment:
Other

0C-23-8

Trial Leaders:
Syma Iqbal

A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic Claudin18.2+ Solid Tumors

Treatment:
Autologous Bone Marrow Transplant

0S-20-8

Trial Leaders:
Gino In

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

Treatment:
Other
Vaccine

2N-22-1

Trial Leaders:
Jorge Nieva

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors

Treatment:
Other

4B-21-3

Trial Leaders:
Hooman Djaladat

Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of Tookad (padeliporfin) Vascular Targeted Photdynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer.

Treatment:
Chemotherapy: Local
Other

4B-22-3

Trial Leaders:
Anishka D'Souza

PhI-133/NCI 10483: Phase Ib trial of Erdafitinib combined with Enfortumab Vedotin following platinum and PD1/L1 inhibitors for metastatic urothelial carcinoma with FGFR2/3 genetic alterations

Treatment:
Immunotherapy

5GYN-23-2

Trial Leaders:
Koji Matsuo

A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

Treatment:
Chemotherapy: Systemic
Other

CTSU-A031702

Trial Leaders:
Anishka D'Souza

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Treatment:
Chemotherapy: Systemic
Immunotherapy

SWOG-S1931

Trial Leaders:
Varsha Tulpule

Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

Treatment:
Chemotherapy: Systemic
Immunotherapy
Surgery

Phase I trials for all solid tumors:


0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0C-18-2

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study of FID-007 in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-18-21

Trial Leaders:
Diana Hanna

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic
Immunotherapy

0C-19-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

Treatment:
(No treatments specified)

0C-19-16

Trial Leaders:
Heinz Josef Lenz

PhI-112: A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-19-6

Trial Leaders:
Anthony El-Khoueiry

A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) with Oral Decitabine in Subjects with Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-19-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with Balstilimab (AGEN2034), an Anti-PD1 Monoclonal Antibody, in Participants With Advanced Cancer

Treatment:
Immunotherapy

0C-20-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Treatment:
Immunotherapy

0C-20-10

Trial Leaders:
Anthony El-Khoueiry

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

Treatment:
Other

0C-20-12

Trial Leaders:
Anthony El-Khoueiry

A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

Treatment:
Other

0C-20-13

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies

Treatment:
Other

0C-20-16

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-20-18

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)

Treatment:
Other

0C-20-19

Trial Leaders:
Jacob Thomas

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab In Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

Treatment:
Other

0C-20-22

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/1b Study of SRF388 in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-20-24

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, as a Single Agent in Subjects With Any Progressive Locally Advanced (Unresectable) or Metastatic Solid Tumors

Treatment:
Immunotherapy

0C-20-3

Trial Leaders:
James Hu

A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-20-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1454

Treatment:
Other

0C-21-12

Trial Leaders:
Anthony El-Khoueiry

A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-21-13

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers

Treatment:
Immunotherapy

0C-21-14

Trial Leaders:
Jacob Thomas

A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-21-17

Trial Leaders:
Heinz Josef Lenz

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Treatment:
Other

0C-21-18

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study of ASP1570 in Participants with Advanced Solid Tumors

Treatment:
Immunomodulator

0C-21-19

Trial Leaders:
Jacob Thomas

A Phase 1/1b Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and / or NRAS Mutation Positive Solid Tumors

Treatment:
Other

0C-21-20

Trial Leaders:
Anthony El-Khoueiry

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-21-8

Trial Leaders:
Heinz Josef Lenz

PhI-129 /NCI 10358: Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)

Treatment:
Other

0C-21-9

Trial Leaders:
Anthony El-Khoueiry

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

Treatment:
Other

0C-22-11

Trial Leaders:
Jacob Thomas

A Phase 1/2 Study of BA3071 in Combination with Nivolumab in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-22-12

Trial Leaders:
Diana Hanna

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of Decoy20 in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-22-13

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-22-16

Trial Leaders:
Anthony El-Khoueiry

A Phase 1B/2, Open-label Study of Q702 in combination with intravenous Pembrolizumab in Patients with Selected Advanced Solid Tumors

Treatment:
Immunotherapy

0C-22-17

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Open-Label, First-in-Human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of SAR444200-Based Regimen in Participants with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-22-19

Trial Leaders:
Anthony El-Khoueiry

First in Human Dose Escalation Study of AU409 in Patients with Advanced Primary Liver Cancers or Advanced Solid Tumor with Liver Predominant Metastatic Disease

Treatment:
Biological Response Modifier

0C-22-2

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-Label Study of the Safety, Tolerability, and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination with Approved Immune Checkpoint Inhibitors in Subjects with Relapsed/Refractory Solid Tumors

Treatment:
Immunotherapy

0C-22-20

Trial Leaders:
Diana Hanna

A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications

Treatment:
Immunotherapy

0C-22-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Cemiplimab in Patients with Advanced Cancers

Treatment:
Immunotherapy

0C-22-4

Trial Leaders:
Diana Hanna

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-22-5

Trial Leaders:
Anthony El-Khoueiry

A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination with a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-22-6

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients with Select Advanced or Metastatic Solid Tumors

Treatment:
Immunotherapy

0C-22-9

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Recommended Phase 2 Dose

Treatment:
Immunotherapy

0C-23-10

Trial Leaders:
Jacob Thomas

A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors

Treatment:
Biological Response Modifier

0C-23-15

Trial Leaders:
Anthony El-Khoueiry

A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors

Treatment:
Immunotherapy

0C-23-2

Trial Leaders:
Anthony El-Khoueiry

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (anti-BTLA antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0C-23-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types

Treatment:
Chemotherapy: Systemic
Immunotherapy

0C-23-4

Trial Leaders:
Anthony El-Khoueiry

Phase I/II First-in-Human Study of TT-10 as a Single Agent in Participants with Advanced Selected Solid Tumors

Treatment:
Immunotherapy

0C-23-5

Trial Leaders:
Anthony El-Khoueiry

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors

Treatment:
Chemotherapy: Local

0C-23-6

Trial Leaders:
Jacob Thomas

Phase 1 Clinical Study on the Tolerability of Utidelone Capsules in Patients with Advanced Solid Tumors

Treatment:
Other

0C-23-7

Trial Leaders:
Anthony El-Khoueiry

A Phase 1-2 dose-escalation and expansion study of ST316 in subjects with selected advanced unresectable and metastatic solid tumors

Treatment:
Other

0C-23-8

Trial Leaders:
Syma Iqbal

A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic Claudin18.2+ Solid Tumors

Treatment:
Autologous Bone Marrow Transplant

0C-23-9

Trial Leaders:
Jacob Thomas

Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors

Treatment:
Immunotherapy

0S-12-3

Trial Leaders:
Peter Conti

18F-FMAU for Imaging in Cancer Patients.

Treatment:
Other

TEST002

Trial Leaders:
Francisco Acosta

Test Protocol 002 Long Protocol Title112

Treatment:
Autologous Bone Marrow Transplant
Biological Response Modifier
Chemotherapy: Local
Genetic




Trials which are NOT treatments of disease. Specimens or information may be collected:


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-12-3

Trial Leaders:
Peter Conti

18F-FMAU for Imaging in Cancer Patients.


0S-12-4

Trial Leaders:
Charite Ricker

USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.


0S-15-12

Trial Leaders:
Bodour Salhia

Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.


0S-15-16

Trial Leaders:
Casey O'Connell

Protocol for Immunology Specimen Collection from Cancer Patients, Patients with Hematologic Diagnoses, and Healthy Normal Controls


0S-20-10

Trial Leaders:
Kimberly  Miller

Social Health, Activity Behaviors, and Quality of Life among Young Adult Cancer Survivors: A Longitudinal Study


0S-22-7

Trial Leaders:
Fumito Ito

Novel Circulating Markers for Monitoring Response to Anti-Cancer Therapy


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


4K-03-2

Trial Leaders:
Eila Skinner

Kidney Cancer Data and Specimen Collection Project.


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.


SWOG-S2013

Trial Leaders:
Varsha Tulpule

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study